[go: up one dir, main page]

NO20034094D0 - Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat - Google Patents

Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat

Info

Publication number
NO20034094D0
NO20034094D0 NO20034094A NO20034094A NO20034094D0 NO 20034094 D0 NO20034094 D0 NO 20034094D0 NO 20034094 A NO20034094 A NO 20034094A NO 20034094 A NO20034094 A NO 20034094A NO 20034094 D0 NO20034094 D0 NO 20034094D0
Authority
NO
Norway
Prior art keywords
epothilone
compositions
derivative
diarrheal agent
agent
Prior art date
Application number
NO20034094A
Other languages
English (en)
Other versions
NO333106B1 (no
NO20034094L (no
Inventor
John David Rothermel
Horst F Schran
Diane Greeley
Tianling Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20034094L publication Critical patent/NO20034094L/no
Publication of NO20034094D0 publication Critical patent/NO20034094D0/no
Publication of NO333106B1 publication Critical patent/NO333106B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20034094A 2001-03-19 2003-09-15 Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat, samt anvendelse derav NO333106B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27715301P 2001-03-19 2001-03-19
US27720701P 2001-03-20 2001-03-20
PCT/EP2002/002977 WO2002074042A2 (en) 2001-03-19 2002-03-18 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative

Publications (3)

Publication Number Publication Date
NO20034094L NO20034094L (no) 2003-09-15
NO20034094D0 true NO20034094D0 (no) 2003-09-15
NO333106B1 NO333106B1 (no) 2013-03-04

Family

ID=26958333

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034094A NO333106B1 (no) 2001-03-19 2003-09-15 Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat, samt anvendelse derav

Country Status (26)

Country Link
US (1) US7030147B2 (no)
EP (1) EP1372650B1 (no)
JP (2) JP2004519493A (no)
KR (1) KR100863089B1 (no)
CN (1) CN100540001C (no)
AT (1) ATE414514T1 (no)
AU (1) AU2002251067B2 (no)
BR (1) BR0208142A (no)
CA (1) CA2440111C (no)
CY (1) CY1108845T1 (no)
CZ (1) CZ302848B6 (no)
DE (1) DE60229922D1 (no)
DK (1) DK1372650T3 (no)
ES (1) ES2318001T3 (no)
HU (1) HUP0303621A3 (no)
IL (1) IL157333A0 (no)
MX (1) MXPA03008462A (no)
NO (1) NO333106B1 (no)
NZ (1) NZ541703A (no)
PT (1) PT1372650E (no)
RU (1) RU2330661C2 (no)
SI (1) SI1372650T1 (no)
SK (1) SK287334B6 (no)
TW (1) TWI331525B (no)
WO (1) WO2002074042A2 (no)
ZA (1) ZA200306318B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
JP4800558B2 (ja) * 2000-08-24 2011-10-26 中外製薬株式会社 環状ペプチド誘導体
ES2384789T3 (es) 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
US6727261B2 (en) * 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
NZ538522A (en) 2002-08-23 2008-03-28 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7550590B2 (en) * 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
ZA200602051B (en) * 2003-08-13 2007-10-31 Takeda Pharmaceutical 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050065144A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
EP1699777B1 (en) * 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
BRPI0418639B8 (pt) * 2004-03-15 2021-05-25 Takeda Pharmaceutical compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
RU2253440C1 (ru) * 2004-03-31 2005-06-10 Открытое Акционерное Общество "Фаберлик" Средство для устранения нарушений нейрогенной и эндокринной регуляции системы капиллярного кровотока
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
WO2007086879A2 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
ZA200802857B (en) * 2005-09-14 2009-09-30 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
HRP20140091T4 (hr) * 2005-09-14 2021-12-24 Takeda Pharmaceutical Company Limited Davanje inhibitora dipeptidil peptidaze
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
AU2008325016A1 (en) * 2007-11-09 2009-05-14 Novartis Ag Corticosteroids to treat epothilone or epothilone derivative induced diarrhea
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
KR101478925B1 (ko) * 2013-12-31 2015-01-08 아주대학교산학협력단 프로테아좀 저해제와 로페라마이드를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301831D0 (sv) * 1993-05-28 1993-05-28 Analytecon S A Pharmaceutical compositions
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
EP1683520B1 (en) * 1996-03-12 2013-11-20 PG-TXL Company, L.P. Water-soluble prodrugs
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6103487A (en) * 1997-08-27 2000-08-15 Merck & Co., Inc. Method of treating cancer
US6127390A (en) * 1997-10-02 2000-10-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
WO1999039694A2 (en) * 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
JP2002533346A (ja) * 1998-12-22 2002-10-08 ノバルティス アクチエンゲゼルシャフト エポシロン誘導体およびそれらの抗腫瘍剤としての使用
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
TWI341728B (en) * 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites

Also Published As

Publication number Publication date
NO333106B1 (no) 2013-03-04
WO2002074042A3 (en) 2003-02-27
RU2003130058A (ru) 2005-04-10
RU2330661C2 (ru) 2008-08-10
ZA200306318B (en) 2005-02-23
JP2010006830A (ja) 2010-01-14
KR100863089B1 (ko) 2008-10-13
CA2440111C (en) 2010-12-07
KR20040025907A (ko) 2004-03-26
BR0208142A (pt) 2004-03-02
PL363427A1 (en) 2004-11-15
TWI331525B (en) 2010-10-11
CY1108845T1 (el) 2014-07-02
IL157333A0 (en) 2004-02-19
HK1061516A1 (en) 2004-09-24
DE60229922D1 (de) 2009-01-02
AU2002251067B2 (en) 2005-05-26
PT1372650E (pt) 2009-02-25
JP2004519493A (ja) 2004-07-02
NO20034094L (no) 2003-09-15
MXPA03008462A (es) 2003-12-08
EP1372650B1 (en) 2008-11-19
NZ541703A (en) 2007-04-27
CZ302848B6 (cs) 2011-12-14
US7030147B2 (en) 2006-04-18
ATE414514T1 (de) 2008-12-15
DK1372650T3 (da) 2009-03-16
EP1372650A2 (en) 2004-01-02
WO2002074042A2 (en) 2002-09-26
SK11702003A3 (sk) 2004-02-03
CZ20032529A3 (cs) 2004-09-15
CN100540001C (zh) 2009-09-16
CA2440111A1 (en) 2002-09-26
SI1372650T1 (sl) 2009-04-30
CN1622805A (zh) 2005-06-01
HUP0303621A3 (en) 2005-03-29
HUP0303621A2 (hu) 2004-03-01
ES2318001T3 (es) 2009-05-01
US20040092478A1 (en) 2004-05-13
SK287334B6 (sk) 2010-07-07

Similar Documents

Publication Publication Date Title
NO20034094L (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20053144D0 (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
DK1564210T3 (da) 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
NO20034433L (no) Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil
DK1412357T3 (da) Beta-aminotetrahydroimidazo-(1,2-a)-pyraziner og tetrahydrotriazolo-(4,3-a)-pyraziner som dipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
DK1414486T3 (da) Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
NO20050427L (no) Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
NO20025150D0 (no) 2-acylindolderivater og deres anvendelse som antitumormidler
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO990440L (no) Preparat som innbefatter mupirocin og klorheksidin
DK1268479T3 (da) Phenylsubstituerede indolizinderivater og deres anvendelse som histamin H3-ligander
NO20021007D0 (no) Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-oner og deres anvendelse som lipasehemmere
NO20043173L (no) Benzotiazol- og benzoksazol-4,7-dionderivater og deres anvendelse som CDC25-fosfataseinhibitorer
NO20005147D0 (no) FremgangsmÕter og sammensetninger som benytter terfenadinmetabolitter i kombinasjon med leukotrienhemmere
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
DK1373249T3 (da) Imidazolidinderivater, deres fremstilling og deres anvendelse som anti-inflammatorisk middel
PA8558501A1 (es) 1,3-diarilprop-2-en1-onas, composiciones que las contienen y su utilizacion

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees